Newsylist real-time news trend intelligence
🔥 Breakout ↑ Rising Business

Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley

Eli Lilly is reportedly nearing an acquisition of the psychedelic drugmaker AtaiBeckley, triggering significant movement in the company's share price.

6sources
6articles
18velocity
+31%since first seen
just nowfirst detected

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

181260Jul 16 11:29Jul 16 12:29 UTC

The brief

Eli Lilly is in discussions to acquire AtaiBeckley, a company focused on the development of psychedelic drugs. Following reports of these negotiations, AtaiBeckley shares experienced substantial growth in after-hours trading.

Coverage from Bloomberg News, Reuters, TradingView, Seeking Alpha, and Yahoo Finance highlights the market reaction, noting significant increases in stock value. Analysts and financial reports have identified the company as a notable stock under $10.

Future developments depend on whether the reported buyout discussions result in a finalized agreement. Coverage does not yet specify the terms of any potential deal or the timeline for a formal announcement.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.

Quick answers

What is driving the movement in AtaiBeckley stock?

The increase in share price is linked to reports regarding potential buyout discussions with Eli Lilly.

Has a deal between Eli Lilly and AtaiBeckley been finalized?

No. Coverage indicates that Eli Lilly is currently nearing a deal, but reports do not confirm a final agreement.

How much has AtaiBeckley's stock risen?

Market reports indicate stock increases ranging between 59% and 66% during after-hours trading.

Coverage (6)

People, places & organizations

Topics

Related trends